Why the study?
Does apixaban provide effective and safe anticoagulation compared to traditional therapies in patients at risk for thromboembolic events?
Population
Patients requiring prevention or treatment of thromboembolic diseases
Comparison
Apixaban vs Traditional anticoagulants
Design
Review
Authors
Loading...
Supports apixaban consideration for anticoagulation; leaves open head-to-head efficacy trials versus traditional agents.
Does apixaban provide effective and safe anticoagulation compared to traditional therapies in patients at risk for thromboembolic events?
Apixaban is a promising oral direct factor Xa inhibitor with predictable pharmacokinetics and pharmacodynamics, offering a convenient alternative to traditional anticoagulants.
Airoldi et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: